| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2023―Apr―28 |
Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond |
Lisa Gieber, Vincent Muturi-Kioi, Shelly Malhotra, Ayesha Sitlani |
| 2 |
[GO] |
2022―Jul―28 |
Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK |
Rajmeet Jandu, Carl Naraynassamy, Nadarajah Sreeharan |
| 3 |
[GO] |
2022―Feb―26 |
The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
William T. Gattrell, Aurélie Barraux, Sam Comley, Michael Whaley, Nicholas Lander |
| 4 |
[GO] |
2021―Dez―31 |
Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond |
Daniel Furtner, Salil Prakash Shinde, Manmohan Singh, Chew Hooi Wong, Sajita Setia |
| 5 |
[GO] |
2021―Sep―27 |
How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream |
Theodore J. Witek |
| 6 |
[GO] |
2021―Aug―28 |
The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic |
Allan Tran, Theodore J. Witek |
| 7 |
[GO] |
2021―Jul―05 |
Preparing for the Next Normal: Transformation in the Role of Medical Affairs Following the COVID-19 Pandemic |
Romik Ghosh, Senthilnathan Mohanasundaram, Sujatha Shetty, Shalini Menon |
| 8 |
[GO] |
2021―Feb―19 |
COVID-19: Reasons for Guarded Optimism |
Noel Snell |
| 9 |
[GO] |
2020―Jun―13 |
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? |
Shubham Atal, Zeenat Fatima |
